Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And now over the coming quarters, we will focus on steadily improving our business fundamentals and our performance as we work to build your confidence in Bioventus |
| Growth was bolstered from higher than adjusted anticipated generator sales at the end of the year |
| And now we look to build on our momentum with stronger execution as we focus on our mission, on accelerating revenue growth and cash flow and on creating shareholder value |
| And Tony and I have had an exceptionally smooth, I'd even say, world-class transition, and I'm grateful to him for that |
| Bioventus is well positioned in large market segments with excellent technology and a talented team who is eager to accelerate the company's growth and profitability across each of our businesses |
| I think we feel good about our revenue growth |
| Consider this, we hold a leadership position across roughly two thirds of our product portfolio, while in the remaining one third of our portfolio, we are growing faster than the market |
| And we are in markets with favorable demographic tailwinds enabling sustained growth |
| In closing, the execution of our business plan in the past year has significantly strengthened our liquidity position |
| This combination of healthy market dynamics, progress with our business fundamentals and exceeding our objectives is providing our team with the energy and the confidence to further advance our business |
| Let me start by saying I am proud of our entire organization for the significant improvement across our commercial business and functions |
| First, accelerating our revenue growth, second, improving our operational efficiency and boosting our future profitability, and third, improving our cash flow and liquidity position |
| First, as we have discussed in the past, 2024 will be the second year of our planned turnaround with a focus on accelerating revenue growth across our business, fueled by increasing growth across our HA and Surgical Solutions businesses, along with continued above-market growth in our International segment |
| And with our improved processes and controls, our visibility into our business has increased, leading to what we believe will be improved predictability as we start the New Year, we plan to enhance our revenue growth and cash flow while we maintain spending discipline |
| We drove a significant improvement across our business in 2023 |
| And we expect that our strong volume growth, combined with improving price dynamics will accelerate revenue as the headwinds from the past year half subside throughout the year |
| Pretty impressive results relative to expectations, certainly, and welcome, Rob |
| We expect the market-leading technology of our ultrasonic platform to continue to produce double-digit growth |
| Meanwhile, the work done by the team to strengthen our bone graft substitutes business enabled us to return to above market growth in the fourth quarter, which we expect to maintain in 2024 |
| And we have a tremendous opportunity to build our International business with expected strong double-digit growth |
| So overall, our financial plan calls for a meaningful increase in our revenue growth compared to the last 2 years |
| We have excellent world-class technology and favorable share positions, customers who understand our value |
| And just like Mark said, the customer feedback during our visits has been extremely positive |
| I mean as you probably know, fantastic proven technology, has excellent brand recognition |
| And while our organization demonstrates fantastic teamwork daily, it's clear we have a significant opportunity to better integrate our business processes across functions and locations to streamline our work and drive speed so that it's easier for our customers to do business with us and so that we can devote more of our energy to generating profitable growth |
| And so when we look into the future, again, we're confident that we can return this back to small single-digit growth, and it's a great product and a lot of positive feedback from the physicians in the field |
| So the portfolio really led by DUROLANE back to the great contract positions we have in the market and with the execution on pulling through volume by our sales team, which we're really proud of |
| And that combination of the market segments we're in, the technology and the favorable share positions really spoke to the potential of the company |
| And that - we haven't had great expectations with that, I'd say, over the last few years, but it continues to outperform our expectations |
| And with the right focus, particularly with commercial execution and operational excellence that there was potential, significant potential to drive shareholder value |
| Statement |
|---|
| Finally, as we previewed on our earnings call last quarter, our International segment fell 4% with constant currency growth down 6% |
| Gross margin came in below our expectations due to transitory inventory write-offs |
| I think we've been disappointed over the last few years where we have had that product declining and has started to return back to at least being even in a slightly positive growth in fourth quarter |
| Shifting to Restorative Therapies, sales fell 16%, driven by the impact of our Wound business divestiture, which accounted for 20 percentage points of the decline |
| And then when talking to the Board and the management team, it was clear to me that some of the headwinds that the company had faced were temporary |
| If you look at fourth quarter specifically, we had a write-off that impacted the fourth quarter margin |
| And then just maybe as a follow-up to that, I think gross margin has seen some fluctuation and headwinds from some of these reimbursement challenges |
| And there are so many challenges for us to tackle, but we will approach every day with a continuous improvement mindset, and we cannot wait to show everyone what Bioventus can and will achieve |
| Adjusted earnings per share were $0.07 for the quarter compared to a loss of $0.02 in the prior year |
| That is really a onetime write-off that was related to our ultrasonics portfolio and really a product transition where we evaluated the old inventory that we had and the potential disruption for customers that we wanted to avoid and looked at the excess inventory and took a onetime write-off in 4Q that should not repeat |
| Our 2023 adjusted gross margin reflects the impact of lower average selling price for the year in our HA franchise |
| Chase Knickerbocker And then maybe how should we think about volume growth for GELSYN this year, as you kind of talked about, there is that kind of headwind as things continue to transition to single-injection products |
| I mean this is another situation |
| There were a few factors |
| Similar to prior years, we expect our first quarter revenue and adjusted EBITDA to be the lowest for the year and the fourth quarter to be the highest for the year, with the second and third quarters looking fairly similar |
| So we're bringing back the appropriate level of focus to the business and now we're going to address some operational inefficiencies along the way in order to return the business to growth |
Please consider a small donation if you think this website provides you with relevant information